MDT

88.35

-0.01%↓

VEEV

227.52

+0.29%↑

A

115.37

+1.06%↑

HQY

88.32

+1.19%↑

PDCO

31.27

+0.06%↑

MDT

88.35

-0.01%↓

VEEV

227.52

+0.29%↑

A

115.37

+1.06%↑

HQY

88.32

+1.19%↑

PDCO

31.27

+0.06%↑

MDT

88.35

-0.01%↓

VEEV

227.52

+0.29%↑

A

115.37

+1.06%↑

HQY

88.32

+1.19%↑

PDCO

31.27

+0.06%↑

MDT

88.35

-0.01%↓

VEEV

227.52

+0.29%↑

A

115.37

+1.06%↑

HQY

88.32

+1.19%↑

PDCO

31.27

+0.06%↑

MDT

88.35

-0.01%↓

VEEV

227.52

+0.29%↑

A

115.37

+1.06%↑

HQY

88.32

+1.19%↑

PDCO

31.27

+0.06%↑

Search

Novartis AG

Abierto

109.87 -0.82

Resumen

Variación precio

24h

Actual

Mínimo

109.17

Máximo

110.72

Métricas clave

By Trading Economics

Ingresos

-369M

2.8B

Ventas

386M

14B

P/B

Media del Sector

18.925

73.239

BPA

1.98

Rentabilidad por dividendo

3.48

Margen de beneficios

20.8

Empleados

75,883

EBITDA

-426M

5.2B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-0.43% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.48%

3.06%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

5.4B

219B

Apertura anterior

110.69

Cierre anterior

109.87

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Novartis AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 feb 2025, 06:57 UTC

Adquisiciones, fusiones, absorciones

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31 ene 2025, 09:49 UTC

Ganancias

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31 ene 2025, 08:06 UTC

Ganancias

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31 ene 2025, 06:32 UTC

Ganancias

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

17 mar 2025, 07:34 UTC

Charlas de Mercado

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4 mar 2025, 18:45 UTC

Ganancias

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11 feb 2025, 09:25 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11 feb 2025, 06:42 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11 feb 2025, 06:22 UTC

Adquisiciones, fusiones, absorciones

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11 feb 2025, 06:20 UTC

Adquisiciones, fusiones, absorciones

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11 feb 2025, 06:19 UTC

Adquisiciones, fusiones, absorciones

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11 feb 2025, 06:18 UTC

Adquisiciones, fusiones, absorciones

Novartis: Deal Is Expected to Close in 1H of 2025

11 feb 2025, 06:18 UTC

Adquisiciones, fusiones, absorciones

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11 feb 2025, 06:17 UTC

Adquisiciones, fusiones, absorciones

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11 feb 2025, 06:16 UTC

Adquisiciones, fusiones, absorciones

Novartis to Buy Anthos Therapeutics for $925M Upfront

11 feb 2025, 06:15 UTC

Adquisiciones, fusiones, absorciones

Novartis to Buy Anthos Therapeutics

4 feb 2025, 15:16 UTC

Principales Noticias

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4 feb 2025, 08:12 UTC

Charlas de Mercado
Ganancias

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31 ene 2025, 13:56 UTC

Ganancias

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31 ene 2025, 09:59 UTC

Acciones populares

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31 ene 2025, 07:50 UTC

Charlas de Mercado

Novartis's Outlook Exceeds Market Views -- Market Talk

31 ene 2025, 07:46 UTC

Charlas de Mercado
Ganancias

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31 ene 2025, 06:03 UTC

Ganancias

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31 ene 2025, 06:02 UTC

Ganancias

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31 ene 2025, 06:02 UTC

Ganancias

Novartis Issues 2025 View

31 ene 2025, 06:02 UTC

Ganancias

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31 ene 2025, 06:02 UTC

Ganancias

Novartis 4Q Oper Pft $3.53B

31 ene 2025, 06:02 UTC

Ganancias

Novartis 4Q Net Pft $2.82B

31 ene 2025, 06:02 UTC

Ganancias

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

31 ene 2025, 06:02 UTC

Ganancias

Novartis 4Q Core Operating Profit $4.86B

Comparación entre iguales

Cambio de precio

Novartis AG previsión

Precio Objetivo

By TipRanks

-0.43% descenso

Estimación a 12 Meses

Media 111 USD  -0.43%

Máximo 125 USD

Mínimo 97 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novartis AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

2 ratings

0

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

108.6463 / 111.415Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.